Atopic Dermatitis

Panelists discuss how the Level Up study demonstrated that patients who didn’t achieve Eczema Area and Severity Index 75 (EASI-75) on dupilumab could be successfully switched to upadacitinib without washout, with two-thirds achieving EASI-75 and one-third achieving EASI-90 within just 4 weeks of switching.

Panelists discuss how switching from biologics to Janus kinase (JAK) inhibitors should be considered when patients don’t achieve adequate disease control within 3 to 6 months, experience tolerability issues, or continue to have significant quality-of-life impacts despite apparent skin improvement.

Panelists discuss how oral Janus kinase (JAK) inhibitors offer advantages over biologics in specific clinical scenarios including patients needing rapid onset of action, those with comorbid arthralgia, head and neck involvement, needle fatigue, and environmental trigger sensitivity due to their broad anti-inflammatory effects.

Panelists discuss how the AHEAD recommendations establish evidence-based treatment targets requiring simultaneous achievement of skin clearance (Eczema Area and Severity Index [EASI]-90) and itch relief (itch score 0-1) within 3 to 6 months, fundamentally changing the standard of care by incorporating patient-reported outcomes alongside physician assessments.

Panelists discuss how Janus kinase (JAK) inhibitors represent a revolutionary advancement in atopic dermatitis treatment by targeting multiple cytokine pathways simultaneously at the intracellular level, offering broader therapeutic coverage than biologics that target only 1 or 2 specific cytokines.

These ADHAND trial data highlight the results of tralokinumab in those with atopic dermatitis on the hands who are candidates for systemic therapy.

Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.

These 16-week findings have been announced by Apogee Therapeutics on APG777 in patients with moderate-to-severe atopic dermatitis.

Following the AAD guideline update on atopic dermatitis treatments, Sidbury speaks to the significance of the guideline recommendations for patients and clinicians.

Sidbury highlights updates to previous guidelines on the management of atopic dermatitis using approved topical and systemic therapies.

This Month in Review summary includes a list of some of the most impactful news in the dermatology space from June 2025.

This 4-year data highlights dupilumab’s efficacy among children under the age of 12 with atopic dermatitis.

At SDPA 2025, Gordon presented on the future of dermatology, discussing current drugs being evaluated for atopic dermatitis, psoriasis, and hidradenitis suppurativa.

Silverberg discussers 16-week data for rezpegaldesleukin in atopic dermatitis from the phase 2b REZOLVE-AD trial.

Amlitelimab shows promise as a safe and effective treatment for moderate-to-severe atopic dermatitis, with sustained benefits post-treatment.

This interview segment at the 2025 SDPA Conference highlights additional insights by Friedman on the management and diagnosis of chronic hand eczema, or CHE.

In an interview conducted at the 2025 SDPA Conference, Friedman provided several insights into management and diagnosis of chronic hand eczema, or CHE.

At SDPA 2025, Candrice Heath, MD, said many clinicians remain unaware of baby perfume traditions that may contribute to persistent symptoms in patients of color.

At SDPA 2025, Candrice Heath, MD, presented on what you can do in your clinic to bridge the gap in pediatric atopic dermatitis among children with darker skin tones.

Rezpegaldesleukin showed significant efficacy in improving EASI scores in moderate-to-severe atopic dermatitis patients.

In this report, Chovatiya highlights lebrikizumab’s evolving role in long-term atopic dermatitis management.

The report highlights lebrikizumab’s potential for sustained disease modification and its evolving role in long-term atopic dermatitis management.

This update by FDA officials extends the review period for ruxolitinib cream as a treatment for atopic dermatitis in children aged 2-11 years.

These data from RAD 2025 highlight upadacitinib’s efficacy in the phase 3 Measure Up 1 and 2 studies for older adults with atopic dermatitis.

This Q&A interview at RAD 2025 features a discussion about a talk titled ‘Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis.’